Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
Inder Kaul, Sharon Sawchak, Christoph U. Correll, Rishi Kakar, Alan Breier, Haiyuan Zhu, Andrew C. Miller, Steven M. Paul, Stephen K. Brannan
Dive into the research topics of 'Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial'. Together they form a unique fingerprint.